Trial Profile
A Randomized, Open-Label, 3-Way Crossover Study in Healthy Older Male Subjects to Evaluate the Bioavailability, Food Effect, Safety and Tolerability of A Solid Dosage Formulation of JNJ-54861911
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Oct 2014
Price :
$35
*
At a glance
- Drugs Atabecestat (Primary) ; Atabecestat (Primary)
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 16 Oct 2014 New trial record